Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma

BackgroundOsteosarcoma is a highly malignant bone neoplasm of children and young adults. It is characterized by extremely complex karyotypes and high frequency of chromosomal amplifications. Currently, only the histological response (degree of necrosis) to therapy represent gold standard for predicting the outcome in a patient with non-metastatic osteosarcoma at the time of definitive surgery. Patients with lower degree of necrosis have a higher risk of relapse and poor outcome even after chemotherapy and complete resection of the primary tumor. Therefore, a better understanding of the underlying molecular genetic events leading to tumor initiation and progression could result in the identification of potential diagnostic and therapeutic targets.MethodsWe used a genome-wide screening method – array based comparative genomic hybridization (array-CGH) to identify DNA copy number changes in 48 patients with osteosarcoma. We applied fluorescence in situ hybridization (FISH) to validate some of amplified clones in this study.ResultsClones showing gains (79%) were more frequent than losses (66%). High-level amplifications and homozygous deletions constitute 28.6% and 3.8% of tumor genome respectively. High-level amplifications were present in 238 clones, of which about 37% of them showed recurrent amplification. Most frequently amplified clones were mapped to 1p36.32 (PRDM16), 6p21.1 (CDC5L, HSPCB, NFKBIE), 8q24, 12q14.3 (IFNG), 16p13 (MGRN1), and 17p11.2 (PMP22 MYCD, SOX1,ELAC27). We validated some of the amplified clones by FISH from 6p12-p21, 8q23-q24, and 17p11.2 amplicons. Homozygous deletions were noted for 32 clones and only 7 clones showed in more than one case. These 7 clones were mapped to 1q25.1 (4 cases), 3p14.1 (4 cases), 13q12.2 (2 cases), 4p15.1 (2 cases), 6q12 (2 cases), 6q12 (2 cases) and 6q16.3 (2 cases).ConclusionsThis study clearly demonstrates the utility of array CGH in defining high-resolution DNA copy number changes and refining amplifications. The resolution of array CGH technology combined with human genome database suggested the possible target genes present in the gained or lost clones.

[1]  Wing Hung Wong,et al.  Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. , 2003, Cancer research.

[2]  A. Huvos,et al.  Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma , 2004, Genes, chromosomes & cancer.

[3]  Allan Bradley,et al.  Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays , 2002, Nature Biotechnology.

[4]  P. Ambros,et al.  Chromosomal regions involved in the pathogenesis of osteosarcomas , 2000 .

[5]  O. Kallioniemi,et al.  Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. , 2000, Cancer genetics and cytogenetics.

[6]  J. Mandel,et al.  Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human. , 1998, Human molecular genetics.

[7]  Ajay N. Jain,et al.  Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. , 2002, Cancer research.

[8]  Ajay N. Jain,et al.  Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. , 2003, Cancer research.

[9]  S. Knuutila,et al.  DNA sequence copy number increase at 8q: A potential new prognostic marker in high‐grade osteosarcoma , 1999, International journal of cancer.

[10]  Wen-Lin Kuo,et al.  Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. , 2003, Cancer research.

[11]  Michael B. Elowitz,et al.  The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Le Paslier,et al.  The gene coding for interferon-gamma is linked to the D12S335 and D12S313 microsatellites and to the MDM2 gene. , 1995, Genomics.

[13]  L. Tsai,et al.  A family of human cdc2‐related protein kinases. , 1992, The EMBO journal.

[14]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[15]  T. Libermann,et al.  ERP, a new member of the ets transcription factor/oncoprotein family: cloning, characterization, and differential expression during B-lymphocyte development , 1994, Molecular and cellular biology.

[16]  S. Knuutila,et al.  Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. , 2002, Cancer genetics and cytogenetics.

[17]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[18]  J. Squire,et al.  High‐resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays , 2003, Genes, chromosomes & cancer.

[19]  G. Wei,et al.  CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons , 1999, International journal of cancer.

[20]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[21]  J. Shah,et al.  Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. , 2001, Cancer research.

[22]  W. Kuo,et al.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.

[23]  M. Rock.  Bone Tumors: Diagnosis, Treatment, and Prognosis , 1992 .

[24]  S. Knuutila,et al.  Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma , 2002 .

[25]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[26]  Y. Nakamura,et al.  Cloning and characterization of BAI2 and BAI3, novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1). , 1997, Cytogenetics and cell genetics.

[27]  S. Knuutila,et al.  Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. , 1995, Cancer research.

[28]  A. Huvos,et al.  Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W V Yotov,et al.  Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma , 1999, Genes, chromosomes & cancer.

[30]  M. Schwab.  Oncogene amplification in solid tumors. , 1999, Seminars in cancer biology.

[31]  S. Coughlin,et al.  A Mammalian Homolog of Fission Yeast Cdc5 Regulates G2 Progression and Mitotic Entry* , 1998, The Journal of Biological Chemistry.

[32]  D. Gisselsson,et al.  Differentially amplified chromosome 12 sequences in low‐ and high‐grade osteosarcoma , 2002, Genes, chromosomes & cancer.

[33]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[34]  P. Sorensen,et al.  Comparative genomic hybridization analysis identifies gains of 1p35 p36 and chromosome 19 in osteosarcoma , 2001 .

[35]  Y. Nakamura,et al.  Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. , 1992, Cancer research.